U.S. Markets closed

Rosetta Genomics Ltd. (ROSG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
2.00+0.07 (+3.63%)
At close: 3:59PM EDT
People also watch
  • 5 million market cap and CEO's salary costing 4 million! cant sustain
  • IGXT (MC $46 M) NDA filing for MEGA thin-flim Cialis (better than Viagra) this month =10++ BAGGER Potential ! PLEASE read this guys and then join us to make big money .GLTA

    2 US-NDA submission within 2 months ,lot of Cash and heavily underpriced at a valuation of just $46 million .1 Big drug partnered with Endo Pharma already under review by FDA market launch expected in 1H 2018 .Load up guys before she the MEGA news hit the wire and thank me later .GL

    Intelgenx (IGXT)

    MarketCap $46 Million
    Cash ~$12 Million (including convertible debt) =cash untill 2021+
    Price: 0.70

    NDA submission for tadalafil (erectile dysfunction) thin-film version of Blockbuster drug Cialis in June or July
    NDA resubmission for Rizaport (migraine) in early Q3
    Partnership for Tadalafil in 2H 2017


    IntelGenx previously confirmed the bioequivalence of Tadalafil to Eli Lilly’s Cialis, which had sales of $1.5-billion in 2016 but faces generic competition in 2020. IntelGenx has an exclusive license for oral films from Lilly for its dosing patent, which would allow Tadalafil to enter the ED market in the U.S. free from patent litigation from Lilly. Dr. Matzen explains that Tadalafil, which offers a discrete dosing alternative, could enter the market in 2018, with up to three years of market exclusivity before Cialis is hit with generic competition.

    Tadalafil is an erectile dysfunction (ED) treatment that boasts bioequivalence with Cialis, the current leading brand, and with a successful biostudy in-hand a 505(b)(2) NDA is set to be filed any day now, meaning that a full launch should be expected in mid-2018. Cialis is already winning-out over Viagra in terms of numbers of prescriptions, which is largely down to price and efficacy, but when Tadalafil comes to market with the same product in a more convenient and discreet delivery mechanism, IntelGenX should see a massive number of customers take-up its services.

    IntelGenx has multi-faceted BD approach for its oral films
    With a burgeoning pipeline of pharmaceutical oral films, IntelGenx’s (OTCQX:IGXT; TSXV:IGX) business development strategy is focused on partnering its product pipeline along with actively meeting with potential partners to explore manufacturing
  • clock running out. bk. massive dillution???seems all remaining options all bad...great job ken. hooe new marriage goes as well as your firsr
  • board i think is even more complacent. #$%$ have they been doing while ken has been playing golf
  • No hopes until Mr. Berlin resigns. We had to give up 4 million to raise his 1 million salary.
    This has been happening for last 3 years. In the process we lost 95% of our market cap!!

    Selling personalizedDX would cover his 6 months salary.
  • guess Morgan Stanley is pumping Jake.... lmao
  • Does anyone know the name of the recent Investor who just paid $5 million cash for the non-secured warrants and stock? If ROSG goes bankrupt, they lose everything. With another few million, they could simply buy the entire company.
  • I also became close to nature, and am now able to appreciate the beauty with which this world is endowed. http://dataunion.tistory.com/7853

    Canadian Pacific Railway Limit NYSE $CP Correlation Histogram
    X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 4,338 NYSE Stocks Price Analysis This stock mode of correlation coefficient is 0.8 In other words, the correlation coefficient of the other stocks
  • Who says ROSG isn't poised for potentially massive upward movement? I started receiving notifications from awesome.stock.s the other week and so far they have presented interesting new trade ideas.
  • Selling PersonlizedDX may not be able cover Mr. Berlin salary for one year. So best is sell PersonalizedDX - Mr. Berlin resigns.
    Burn rate would go down by 40% and by Q4 they will be breakeven ( 700k revenue from Reveal an 600k burn rate per month )
    Problem with Mr. Berlin
    1. 10 years of lying
    2. Worked with Aegis and Cantor - sold them stocks at 1/4 the market price ( like there is no tomorrow )
    3. Wrong decision ( ex. buying PersonizedDX, focusing on wrong stuff )
    4. Did not care to cust cost ( whose money is it ) in 2015 we had > 20million cash
    5. Never bought stocks ( and to the world he was telling to buy )
  • Morgan Stanley filed a 13G claiming 5% ownership of commkn stock with the SEC... anyone verify? I read it off a lo k in stocktwits.
  • "powder keg", Jason, might just be the right words, at this $5 million market cap. The facts: just about No debt; Regulatory approvals; Patents; Growing revenues. Labs in production doing thousands of tests annually, and a dozen seasoned sales people.
  • Pumpers gonna pump
  • not much advantage in a Bankruptcy filing here... Rosetta has less than $4 million in debt. Its a $1 million monthly cash burn rate that is the crisis at hand without cash in the bank. Good luck to Ken and Run during June to close a deal !! Sell the darn company if you have to!
  • i would encourage you to call mgmt..since we have not had a call in a long time....vcyt gets about 3k per test. we are lucky to get 1500....you are right as they begin to sell and achieve reimbursements from major carriers that number will go up...but we are probably a year ig not more from that..and we have almost no cash
  • May 22, 2017
    Rosetta Genomics Plans to Sell PersonalizeDx Business
  • I think where you may be somewhat misguided, Michael, is the difference between gross billings and accrued revenues. Rosetta's gross billings are much higher than accrued revenues because they product is brand new and it is therefore taking awhile to collect payments. This will improve over time. Very typical actually for a new diagnostic product in the industry.
  • Are we trading at the equivalent of 15 cents or so pre split?
  • this thing is ready to explode. 1.86M float (2.3M o/s); market cap 4.8M, RosettaGX Reveal Revenues exploding (guiding $4-5M in Reveal revenues in '17 with 2,500-3,500 units sold at $3,000 a pop), Total revenue for '17 likely about $10-11 million. Reveal could significantly cut into VCYT's Afirma in the coming years, which btw sells approximately $16M PER QUARTER. ROSG sitting here at 4 million and change market cap with 1.8M shares in the float. This is a powder keg waiting to fire.
  • Michael, you are misguided. It's important to listen to the CCs. Really dissect everything. From the September '16 CC: Mike Petusky, Barrington Research - Analyst [28]


    Good afternoon, guys. Hey, so on the Reveal revenues for the second quarter, I mean can you give sort of a ballpark of how many orders are represented there so we can kind of get a little bit of a sense of what you're actually getting paid for test? I mean are we talking -- can you give a ballpark? I mean, does that represent 50 orders, 75 orders, may be give a range?


    Ken Berlin, Rosetta Genomics Ltd - CEO [29]


    Well, I can tell you on average and we'll give it for the year-to-date because we have that data. Year-to-date, we're getting paid on average $3,000 when we get paid for Reveal.